BamSEC and AlphaSense Join Forces
Learn More

Akero Therapeutics Inc. – Material Contracts

Formerly NASDAQ: AKRO
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 4 pages Akero Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 10-Q 3 pages Akero Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.2
from 10-Q 16 pages Warrant Agreement to Purchase Shares of the Common Stock of Akero Therapeutics, Inc. Dated as of March 12, 2024 (The “Effective Date”) Section 1. Grant of the Right to Purchase Common Stock
12/34/56
EX-10.4
from 10-Q 17 pages Warrant Agreement to Purchase Shares of the Common Stock of Akero Therapeutics, Inc. Dated as of June 15, 2022
12/34/56
EX-10.3
from 10-Q 17 pages Warrant Agreement to Purchase Shares of the Common Stock of Akero Therapeutics, Inc. Dated as of June 15, 2022
12/34/56
EX-10.2
from 10-Q 65 pages Agreement
12/34/56
EX-10.1
from 8-K 31 pages Securities Purchase Agreement
12/34/56
EX-10.10
from 10-K 2 pages Akero Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.12
from 10-K 102 pages 601 Gateway Boulevard Office Lease
12/34/56
EX-10.11
from 10-K 2 pages Akero Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.10
from S-1/A 11 pages Amended and Restated Employment Agreement
12/34/56
EX-10.9
from S-1/A 13 pages Amended and Restated Employment Agreement
12/34/56
EX-10.8
from S-1/A 11 pages [Amended and Restated] Employment Agreement
12/34/56
EX-10.6
from S-1/A 2 pages Akero Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.3
from S-1/A 11 pages Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 38 pages Akero Therapeutics, Inc. 2019 Stock Option and Incentive Plan
12/34/56
EX-10.9
from S-1 76 pages Certain Confidential Portions of This Exhibit Were Omitted and Replaced With “[***]”. a Complete Version of This Exhibit Has Been Filed Separately With the Secretary of the Securities and Exchange Commission Pursuant to an Application Requesting Confidential Treatment Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended. Exclusive License Agreement by and Between Amgen Inc. and Akero Therapeutics, Inc. Dated as of June 7, 2018 I
12/34/56
EX-10.7
from S-1 24 pages Sublease Agreement
12/34/56
EX-10.5
from S-1 3 pages Akero Therapeutics, Inc. Senior Executive Cash Incentive Bonus Plan
12/34/56
EX-10.4
from S-1 26 pages Akero Therapeutics, Inc. Form of Director Indemnification Agreement
12/34/56